Rhumbline Advisers Boosts Stake in Cerus Corporation $CERS

Rhumbline Advisers lifted its position in Cerus Corporation (NASDAQ:CERS) by 5.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 251,907 shares of the biotechnology company’s stock after purchasing an additional 13,112 shares during the quarter. Rhumbline Advisers owned 0.13% of Cerus worth $350,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of CERS. Ameriprise Financial Inc. purchased a new position in shares of Cerus in the 4th quarter worth about $40,000. BNP Paribas Financial Markets boosted its holdings in shares of Cerus by 13.5% in the 4th quarter. BNP Paribas Financial Markets now owns 206,472 shares of the biotechnology company’s stock worth $318,000 after purchasing an additional 24,575 shares in the last quarter. Deutsche Bank AG boosted its holdings in shares of Cerus by 70.9% in the 4th quarter. Deutsche Bank AG now owns 161,381 shares of the biotechnology company’s stock worth $249,000 after purchasing an additional 66,961 shares in the last quarter. Millennium Management LLC boosted its holdings in shares of Cerus by 52.1% in the 4th quarter. Millennium Management LLC now owns 2,877,932 shares of the biotechnology company’s stock worth $4,432,000 after purchasing an additional 986,286 shares in the last quarter. Finally, ProShare Advisors LLC boosted its holdings in shares of Cerus by 49.0% in the 4th quarter. ProShare Advisors LLC now owns 50,817 shares of the biotechnology company’s stock worth $78,000 after purchasing an additional 16,720 shares in the last quarter. 78.37% of the stock is currently owned by hedge funds and other institutional investors.

Cerus Price Performance

CERS opened at $1.54 on Thursday. The stock has a 50-day moving average price of $1.31 and a 200-day moving average price of $1.35. Cerus Corporation has a 12-month low of $1.12 and a 12-month high of $2.24. The company has a current ratio of 2.00, a quick ratio of 1.35 and a debt-to-equity ratio of 1.01. The stock has a market capitalization of $295.22 million, a P/E ratio of -15.40 and a beta of 1.63.

Cerus (NASDAQ:CERS) last posted its quarterly earnings data on Tuesday, August 5th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.01). Cerus had a negative return on equity of 33.77% and a negative net margin of 9.81%.The firm had revenue of $60.10 million during the quarter, compared to analysts’ expectations of $51.80 million. Cerus has set its FY 2025 guidance at EPS. Equities analysts predict that Cerus Corporation will post -0.08 earnings per share for the current fiscal year.

About Cerus

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.